Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.52
APPY's Cash to Debt is ranked higher than
67% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.74 vs. APPY: 5.52 )
APPY' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 5.52

Equity to Asset 0.70
APPY's Equity to Asset is ranked higher than
75% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. APPY: 0.70 )
APPY' s 10-Year Equity to Asset Range
Min: -0.05   Max: 0.85
Current: 0.7

-0.05
0.85
F-Score: 4
Z-Score: -0.76
M-Score: -1.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -8583.69
APPY's Operating margin (%) is ranked lower than
56% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.84 vs. APPY: -8583.69 )
APPY' s 10-Year Operating margin (%) Range
Min: -14454.84   Max: 17.54
Current: -8583.69

-14454.84
17.54
Net-margin (%) -8616.31
APPY's Net-margin (%) is ranked lower than
56% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. APPY: -8616.31 )
APPY' s 10-Year Net-margin (%) Range
Min: -14858.06   Max: 8.99
Current: -8616.31

-14858.06
8.99
ROE (%) -93.81
APPY's ROE (%) is ranked lower than
51% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. APPY: -93.81 )
APPY' s 10-Year ROE (%) Range
Min: -302.97   Max: 8.04
Current: -93.81

-302.97
8.04
ROA (%) -65.18
APPY's ROA (%) is ranked higher than
51% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. APPY: -65.18 )
APPY' s 10-Year ROA (%) Range
Min: -117.03   Max: 5.09
Current: -65.18

-117.03
5.09
ROC (Joel Greenblatt) (%) -533.88
APPY's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. APPY: -533.88 )
APPY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -533.88   Max: 23.23
Current: -533.88

-533.88
23.23
Revenue Growth (%) -68.80
APPY's Revenue Growth (%) is ranked higher than
51% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. APPY: -68.80 )
APPY' s 10-Year Revenue Growth (%) Range
Min: -68.8   Max: -2.3
Current: -68.8

-68.8
-2.3
EBITDA Growth (%) -58.40
APPY's EBITDA Growth (%) is ranked lower than
52% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. APPY: -58.40 )
APPY' s 10-Year EBITDA Growth (%) Range
Min: -58.4   Max: 43.8
Current: -58.4

-58.4
43.8
EPS Growth (%) -58.60
APPY's EPS Growth (%) is ranked lower than
52% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. APPY: -58.60 )
APPY' s 10-Year EPS Growth (%) Range
Min: -58.6   Max: 37.8
Current: -58.6

-58.6
37.8
» APPY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

APPY Guru Trades in

APPY Guru Trades in

Q3 2012

APPY Guru Trades in Q3 2012

Jim Simons 45,785 sh (New)
» More
Q4 2012

APPY Guru Trades in Q4 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with APPY



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.80
APPY's P/B is ranked higher than
75% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. APPY: 3.80 )
APPY' s 10-Year P/B Range
Min: 0.85   Max: 117.07
Current: 3.8

0.85
117.07
P/S 193.30
APPY's P/S is ranked lower than
55% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.55 vs. APPY: 193.30 )
APPY' s 10-Year P/S Range
Min: 0   Max: 346.37
Current: 193.3

0
346.37
EV-to-EBIT -3.99
APPY's EV-to-EBIT is ranked higher than
51% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. APPY: -3.99 )
APPY' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.99

Current Ratio 7.84
APPY's Current Ratio is ranked higher than
92% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. APPY: 7.84 )
APPY' s 10-Year Current Ratio Range
Min: 0.31   Max: 16.33
Current: 7.84

0.31
16.33
Quick Ratio 7.84
APPY's Quick Ratio is ranked higher than
92% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. APPY: 7.84 )
APPY' s 10-Year Quick Ratio Range
Min: 0.08   Max: 16.01
Current: 7.84

0.08
16.01

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.80
APPY's Price/Net Cash is ranked higher than
93% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. APPY: 5.80 )
APPY' s 10-Year Price/Net Cash Range
Min: 1.76   Max: 51.79
Current: 5.8

1.76
51.79
Price/Net Current Asset Value 5.80
APPY's Price/Net Current Asset Value is ranked higher than
91% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. APPY: 5.80 )
APPY' s 10-Year Price/Net Current Asset Value Range
Min: 1.76   Max: 48.57
Current: 5.8

1.76
48.57
Price/Tangible Book 4.30
APPY's Price/Tangible Book is ranked higher than
79% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.20 vs. APPY: 4.30 )
APPY' s 10-Year Price/Tangible Book Range
Min: 1.52   Max: 97.5
Current: 4.3

1.52
97.5
Price/Median PS Value 0.80
APPY's Price/Median PS Value is ranked higher than
54% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. APPY: 0.80 )
APPY' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 7.83
Current: 0.8

0.26
7.83
Forward Rate of Return (Yacktman) -338.78
APPY's Forward Rate of Return (Yacktman) is ranked lower than
54% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.93 vs. APPY: -338.78 )
APPY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.5   Max: -5.3
Current: -338.78

-13.5
-5.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AP4B.Germany
Venaxis Inc was organized on July 24, 2000, as a Colorado corporation. In December 2012, the Company's name was changed to Venaxis, Inc., from AspenBio Pharma, Inc. The Company is in the business of development and commercialization of innovative products that address unmet diagnostic and therapeutic needs. The Company's lead product candidate, APPY1, is designed to be a novel blood-based diagnostic test that, if successfully cleared to be marketed by the United States Food and Drug Administration (FDA), will aid, through the test's negative predictive value, in the evaluation of low risk patients initially suspected of having acute appendicitis, thereby helping address the difficult challenge of triaging possible acute appendicitis patients in the hospital emergency department or urgent care settings. The APPY1, is intended to be used by emergency department and urgent care physicians to aid them in the evaluation of possible appendicitis in children, adolescent and young adult patients (ages 2 - 20) that present with abdominal pain. The FDA has regulatory marketing authority in the United States over its APPY1 products. The Company operates under ISO9001-4385 standards for cGMP manufacturing of medical devices. The Company is subject to various environmental laws pertaining to the disposal of hazardous medical waste. It contracts for disposal of hazardous waste with a licensed disposal facility.
» More Articles for APPY

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD Jul 09 2012 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Nov 05 2010 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Aug 05 2010 
Weekly CFO Buys Highlight: AspenBio Pharma, Solarwinds, Affymetrix, Cascade Financial Corp., Bank of Jul 31 2010 
advise??? Apr 28 2010 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Nov 05 2009 
AspenBio Pharma Inc. Reports Operating Results (10-Q) Aug 07 2009 
AspenBio Pharma Inc. (APPY) CEO Daryl Faulkner buys 10,000 Shares May 21 2009 
AspenBio Pharma Inc. (APPY) COO & Chief Medical Officer Robert Frederick Caspari buys 3,200 Shares May 19 2009 

More From Our Partners
Worst Performing Industries For July 16, 2014 Jul 16 2014 - BENZINGA

More From Other Websites
Venaxis Reports on Recent FDA Submission Activities Jul 16 2014
Venaxis Reports on Recent FDA Submission Activities Jul 16 2014
VENAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 16 2014
Venaxis to Present at ICV Company Outreach Summit Jul 01 2014
Venaxis to Present at ICV Company Outreach Summit Jul 01 2014
VENAXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... Jun 26 2014
VENAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits May 28 2014
Venaxis to Participate in 11th Annual Craig-Hallum Institutional Investor Conference May 21 2014
VENAXIS, INC. Financials May 20 2014
VENAXIS, INC. Files SEC form 10-Q, Quarterly Report May 12 2014
Agios Pharmaceuticals (AGIO) Crumbles: Stock Falls by 6.0% Apr 25 2014
Weakness Seen in Unilife (UNIS): Stock Tumbles 10.9% Apr 23 2014
VENAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 08 2014
Venaxis, Inc. Closes Public Offering of Common Shares Apr 08 2014
VENAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Apr 03 2014
Why Venaxis (APPY) Stock Is Down Today Apr 03 2014
Venaxis, Inc. Prices $20.0 Million Public Offering of Common Shares Apr 03 2014
Venaxis, Inc. Announces Proposed Public Offering of Common Shares Apr 02 2014
Venaxis Files for FDA Clearance of APPY1 Test Mar 31 2014
VENAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 31 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide